These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 28213368)

  • 21. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
    Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
    Chan YH; Yeh YH; See LC; Wang CL; Chang SH; Lee HF; Wu LS; Tu HT; Kuo CT
    J Am Coll Cardiol; 2016 Nov; 68(21):2272-2283. PubMed ID: 27884245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
    Go AS; Singer DE; Toh S; Cheetham TC; Reichman ME; Graham DJ; Southworth MR; Zhang R; Izem R; Goulding MR; Houstoun M; Mott K; Sung SH; Gagne JJ
    Ann Intern Med; 2017 Dec; 167(12):845-854. PubMed ID: 29132153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J; Giroud M; de Pouvourville G
    Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
    Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S;
    Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).
    Nagarakanti R; Wallentin L; Noack H; Brueckmann M; Reilly P; Clemens A; Connolly SJ; Yusuf S; Ezekowitz MD
    Am J Cardiol; 2015 Oct; 116(8):1204-9. PubMed ID: 26282726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
    JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
    Clemens A; Peng S; Brand S; Brueckmann M; Kansal A; Lim J; Noack H; Sander S; Sorensen S
    Am J Cardiol; 2014 Sep; 114(6):849-55. PubMed ID: 25103918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
    Hori M; Connolly SJ; Zhu J; Liu LS; Lau CP; Pais P; Xavier D; Kim SS; Omar R; Dans AL; Tan RS; Chen JH; Tanomsup S; Watanabe M; Koyanagi M; Ezekowitz MD; Reilly PA; Wallentin L; Yusuf S;
    Stroke; 2013 Jul; 44(7):1891-6. PubMed ID: 23743976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
    Chan PH; Huang D; Hai JJ; Li WH; Yin LX; Chan EW; Wong IC; Lau CP; Chiang CE; Zhu J; Tse HF; Siu CW
    Heart Rhythm; 2016 Feb; 13(2):366-73. PubMed ID: 26392326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
    Mumoli N; Mastroiacovo D; Tamborini-Permunian E; Vitale J; Giorgi-Pierfranceschi M; Cei M; Dentali F
    J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):467-477. PubMed ID: 28509761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
    Ferreira J; Ezekowitz MD; Connolly SJ; Brueckmann M; Fraessdorf M; Reilly PA; Yusuf S; Wallentin L;
    Eur J Heart Fail; 2013 Sep; 15(9):1053-61. PubMed ID: 23843099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.
    Kent AP; Brueckmann M; Fraessdorf M; Connolly SJ; Yusuf S; Eikelboom JW; Oldgren J; Reilly PA; Wallentin L; Ezekowitz MD
    J Am Coll Cardiol; 2018 Jul; 72(3):255-267. PubMed ID: 30012318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
    Hohnloser SH; Steg PG; Oldgren J; Nickenig G; Kiss RG; Ongen Z; Navarro Estrada JL; Oude Ophuis T; Lip GYH; Nordaby M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1553-1561. PubMed ID: 31439336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.